1.	Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras, BRAF Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, ISRCTN83171665, EU-20960, NCT00975897
2.	Phase III Randomized Study of Cisplatin With or Without Monoclonal Antibody C225 in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5397, E5397, NCT00003809
3.	Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067468, UAB-9901, IMCL-CP02-9815, NCI-G99-1657, NCT00004227
4.	Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000350016, U10CA031946, CALGB-80203, NCT00077233
5.	Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225-006, NCT00063141
6.	Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225-014, NCT00061815
7.	Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 69 Sponsor: NCI Protocol IDs: NCI-2009-00639, N0147, U10CA025224, CDR0000355132, NCCTG-N0147, ECOG-N0147, NCT00079274
8.	Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13423, I4E-MC-JXBC, CP02-0452, NCT00095199
9.	Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225-099, NCT00112294
10.	Phase III Randomized Study of Continuous Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (OxMdG) or Oxaliplatin and Capecitabine (XELOX) With Versus Without Cetuximab Versus Intermittent Combination Chemotherapy With OxMdG or XELOX as First-Line Therapy in Patients with Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-COIN-CR10, EU-20516, NCT00182715, EUDRACT-2004-002951-16, ISRCTN27286448, COIN
11.	Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-002, NCT00122460
12.	FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 to 74 Sponsor: Other Protocol IDs: Nordic VII, EudraCT no.: 2005-000117-34, NCT00145314
13.	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-046, NCT00148798
14.	Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CAIRO2, NCT00208546
15.	Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-013, NCT00154102
16.	Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery Phase: Phase III Type: Treatment Status: Completed Age: 18 to 74 Sponsor: Other Protocol IDs: CDR0000453839, FFCD-PETACC-8, EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
17.	Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-C80405, C80405, SWOG-C80405, NCT00265850
18.	Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 05-041, NCT00252564
19.	Phase III Randomized Study of Concurrent Accelerated Fractionated Radiotherapy and Cisplatin With Versus Without Cetuximab in Patients With Stage III or IV Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0522, RTOG 0522, NCT00265941
20.	Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
21.	Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy (Treatment Arm III Closed to Accrual as of 4/20/2009) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0600, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
22.	Phase III Randomized Study of High- Versus Standard-Dose Conformal Radiotherapy With Concurrent and Consolidation Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Cetuximab in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer (Arms II and IV closed to accrual effective 6/17/11) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0617, RTOG 0617, NCCTG-N0628, CALGB-30609, NCT00533949
23.	Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CO20, CAN-NCIC-CO20, CAN-NCIC-CA182009, CDR0000590316, NCT00640471
24.	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200048-052, NCT00678535
25.	Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62240-506, NCT00820755